APA (7th ed.) Citation

Gettinger, S., Beck, T., Yang, X., Telivala, B., Morgensztern, D., Velcheti, V., . . . Ranck, A. (2018). 1503TiPCheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy292.124

Chicago Style (17th ed.) Citation

Gettinger, S., et al. "1503TiPCheckMate 592: A Phase II Exploratory Study of Biomarkers Associated with the Efficacy of First-line Nivolumab (nivo) Plus Ipilimumab (ipi) in Patients (pts) with Stage IV or Recurrent NSCLC." Annals of Oncology 29 (2018): N.PAG. https://doi.org/10.1093/annonc/mdy292.124.

MLA (9th ed.) Citation

Gettinger, S., et al. "1503TiPCheckMate 592: A Phase II Exploratory Study of Biomarkers Associated with the Efficacy of First-line Nivolumab (nivo) Plus Ipilimumab (ipi) in Patients (pts) with Stage IV or Recurrent NSCLC." Annals of Oncology, vol. 29, 2018, p. N.PAG, https://doi.org/10.1093/annonc/mdy292.124.